2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15685A
    Ripasudil free base 223645-67-8
    Ripasudil free base (K-115 free base) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.
    Ripasudil free base
  • HY-156913
    Casein kinase 1δ-IN-13 345616-08-2
    Casein kinase 1δ-IN-13 (compound 401) is a Casein kinase 1δ inhibitor. Casein kinase 1δ-IN-13 can be used in neurodegenerative disease research.
    Casein kinase 1δ-IN-13
  • HY-156983
    MRS 5980 1639420-13-5
    MRS 5980 is an A3AR agonist with a Ki value of 0.7 nM. MRS 5980 has oral activity.
    MRS 5980
  • HY-156984
    Monometacrine 4757-49-7
    Monometacrine is a cholesterol esterase inhibitor. Monometacrine has antidepressant effect.
    Monometacrine
  • HY-157087
    AChE/MAO-B-IN-4
    AChE/MAO-B-IN-4 (compound 4a) is a selective dual AChE and MAO-B inhibitor. AChE/MAO-B-IN-4 shows no significant inhibition activity against BChE and h-MAO-A. AChE/MAO-B-IN-4 can be used for the Alzheimer’s disease (AD) research.
    AChE/MAO-B-IN-4
  • HY-157089
    AChE/MAO-B-IN-5
    AChE/MAO-B-IN-5 is a dual inhibitor of AChE and MAO-B. AChE/MAO-B-IN-5 can used in study Alzheimer’s disease.
    AChE/MAO-B-IN-5
  • HY-157090
    AChE/MAO-B-IN-6
    AChE/MAO-B-IN-6 (compound 3a) is a dual inhibitor of AChE and h-MAO-B with potential to inhibit Alzheimer's disease.
    AChE/MAO-B-IN-6
  • HY-157168
    TrkA-IN-6
    TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM.
    TrkA-IN-6
  • HY-157172
    MorHap
    MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA)-containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection.
    MorHap
  • HY-15720B
    Glycyl H-1152 hydrochloride 913844-45-8
    Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride.
    Glycyl H-1152 hydrochloride
  • HY-15728S
    Radotinib-d6 2754051-83-5
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
    Radotinib-d6
  • HY-157296
    AChE-IN-47 3033056-55-9
    AChE-IN-47 (compound g17) is a AChE inhibitor with the IC50 of 0.24 μM. AChE-IN-47 inhibits amyloid β peptides self-aggregation. AChE-IN-47 displays neuroprotective effects and effectively suppresses the intracellular accumulation of reactive oxygen species.
    AChE-IN-47
  • HY-157326
    hMAO-B-IN-6 2764830-43-3
    hMAO-B-IN-6 (compound 17d) is a potent and selective inhibitor of hMAO-B with an IC50 of 67.02 nM. hMAO-B-IN-6 significantly improves Scopolamine (HY-N0296)-induced cognitive impairment in AD mice.
    hMAO-B-IN-6
  • HY-157343
    GD3 Ganglioside 62010-37-1
    GD3 Ganglioside is a prominent ganglioside of human melanoma. GD3 Ganglioside is an inducer of mitochondrial permeability. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis.
    GD3 Ganglioside
  • HY-157382
    AChE-IN-51
    AChE-IN-51 (compound 8C) is an orally active, non-competitive inhibitor of AChE and BChE (IC50: 84 nM, 97 nM). It also inhibits MMP-2 and amyloid Aβ1-42 aggregates (IC50: 724 nM, 302 nM). AChE-IN-51 has low cytotoxicity and in silico predicted blood-brain barrier permeability. Can be used for research on diseases such as Alzheimer's disease (AD).
    AChE-IN-51
  • HY-157384
    BChE-IN-22
    BChE-IN-22 (compound 5A) is a selective eqBChE inhibitor (IC50: 0.53 μM), has anti-inflammatory and neuroprotective activities. BChE-IN-22 can inhibit cell damage caused by Aβ25-35 (HY-P0128) and improve cognitive dysfunction caused by Scopolamine (HY-N0296).
    BChE-IN-22
  • HY-157400
    hMAO-B-IN-7 2955577-14-5
    hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC50 value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research.
    hMAO-B-IN-7
  • HY-157425
    5-HT2CR agonist 1 1216074-15-5
    5-HT2CR agonist 1 (compound 8), a 7-chloro analogue, is a selective 5-HT2CR partial agonist (Emax=71.09%) with an EC50 value of 121.5 nM and no observed activity toward 5-HT2AR or 5-HT2BR. 5-HT2CR agonist 1 exhibits no recruitment activity for β-arrestin and shows low inhibition of hERG at 10 μM.
    5-HT2CR agonist 1
  • HY-157429
    25N-N1-Nap 2865185-31-3
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice.
    25N-N1-Nap
  • HY-157430
    BET-IN-21 3014815-06-3
    BET-IN-21 (compound 16) is a blood-brain barrier-permeable extra terminal domain (BET) inhibitor with the Ki of 230 nM. BET-IN-21 inhibits microglia activation and has ameliorative effects on experimental autoimmune encephalomyelitis mice.
    BET-IN-21
Cat. No. Product Name / Synonyms Application Reactivity